Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy

CMT1A patients commonly share PMP22 genetic overloading but they show phenotypic heterogeneity and variability in PMP22 mRNA and protein expression. Moreover, PMP22 mRNA levels do not correlate with clinical outcome measures in these patients, suggesting their uselessness as a disease biomarker. Thus, in‐depth analysis of PMP22 transcription and translation might help to define its pathogenic role in CMT1A. We focused on the alternative splicing of PMP22 gene to verify whether mRNA processing is altered in CMT1A. We identified three new PMP22 transcripts enriched in human sural nerve biopsies. One of them was an untranslated variant, whereas the other two originated from a PMP22 undescribed exon and encoded for a new putative protein localized in the endoplasmic reticulum. As splicing events in the PMP22 gene are differently regulated in tissues and during development, we analyzed the levels of PMP22 transcripts and their splicing pattern in human and experimental CMT1A. We found an altered PMP22 splicing ratio in the CMT1A rat. In addition, we showed a remarkable derangement in rat QKI expression, which is a critical regulator of splicing during myelination. Overall, our data suggest that an alteration of mRNA processing could be a pathogenic mechanism in CMT1A.

[1]  D. Ledbetter,et al.  Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A , 1992, Nature Genetics.

[2]  T. Bird,et al.  Peripheral myelin protein–22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot–Marie–Tooth 1A , 1992, Nature Genetics.

[3]  J. Lupski,et al.  Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. , 1994, The Journal of biological chemistry.

[4]  C. Schneider,et al.  Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A. , 1995, Genes & development.

[5]  K. Nave,et al.  A Transgenic Rat Model of Charcot-Marie-Tooth Disease , 1996, Neuron.

[6]  K. Artzt,et al.  Neural Cell Type-Specific Expression of QKI Proteins Is Altered in quakingviable Mutant Mice , 1996, The Journal of Neuroscience.

[7]  H. Kiyosawa,et al.  Primate origin of the CMT1A-REP repeat and analysis of a putative transposon-associated recombinational hotspot. , 1996, Human molecular genetics.

[8]  A. Harding,et al.  The phenotypic manifestations of chromosome 17p11.2 duplication. , 1997, Brain : a journal of neurology.

[9]  Y. Agid,et al.  Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. , 1997, Brain : a journal of neurology.

[10]  T. Anani,et al.  Ultrastructural Immunocytochemical Abnormalities of Peripheral Myelin Proteins in Hereditary Sensory‐Motor Neuropathies: 12 cases , 1999, Annals of the New York Academy of Sciences.

[11]  M. Shy,et al.  Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis , 2000, Journal of neuroscience research.

[12]  A. Hudder,et al.  Analysis of a Charcot-Marie-Tooth Disease Mutation Reveals an Essential Internal Ribosome Entry Site Element in the Connexin-32 Gene* , 2000, The Journal of Biological Chemistry.

[13]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[14]  Jo Vandesompele,et al.  Quantification of splice variants using real-time PCR , 2001, Nucleic Acids Res..

[15]  K. Huehne,et al.  Transcriptional startpoints and methylation patterns in the PMP22 promoters of peripheral nerve, leukocytes and tumor cell lines. , 2001, International journal of molecular medicine.

[16]  S. Scherer,et al.  Inherited neuropathies. , 2002, Neurologic clinics.

[17]  C. Schneider,et al.  Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22 , 2003, Journal of Cell Science.

[18]  Sean P Ryder,et al.  Specificity of the STAR/GSG domain protein Qk1: implications for the regulation of myelination. , 2004, RNA.

[19]  G. Mancardi,et al.  Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease , 2004, Neurobiology of Disease.

[20]  S. Richard,et al.  Target RNA motif and target mRNAs of the Quaking STAR protein , 2005, Nature Structural &Molecular Biology.

[21]  K. Nave,et al.  Experimental Charcot–Marie–Tooth type 1A: A cDNA microarrays analysis , 2005, Molecular and Cellular Neuroscience.

[22]  L. Santoro,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. , 2006, Pharmacological research.

[23]  F. Glorieux,et al.  CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta , 2006, Cell.

[24]  N. Jareborg,et al.  Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Delorenzi,et al.  Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. , 2007, American journal of human genetics.

[26]  S. Scherer,et al.  Molecular mechanisms of inherited demyelinating neuropathies , 2008, Glia.

[27]  Yue Feng,et al.  Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development. , 2008, Future neurology.

[28]  Lan Lin,et al.  Predicting Functional Alternative Splicing by Measuring RNA Selection Pressure from Multigenome Alignments , 2009, PLoS Comput. Biol..

[29]  J. Pal,et al.  Role of 5′‐ and 3′‐untranslated regions of mRNAs in human diseases , 2009, Biology of the cell.

[30]  M. Cilli,et al.  Impaired Expression of Ciliary Neurotrophic Factor in Charcot-Marie-Tooth Type 1A Neuropathy , 2009, Journal of neuropathology and experimental neurology.

[31]  A. Schenone,et al.  P2X7-mediated Increased Intracellular Calcium Causes Functional Derangement in Schwann Cells from Rats with CMT1A Neuropathy* , 2009, The Journal of Biological Chemistry.

[32]  I. Katona,et al.  PMP22 expression in dermal nerve myelin from patients with CMT1A. , 2009, Brain : a journal of neurology.

[33]  S. Richard,et al.  The QKI-6 and QKI-7 RNA Binding Proteins Block Proliferation and Promote Schwann Cell Myelination , 2009, PloS one.

[34]  S. Regis,et al.  PLP1 gene duplication causes overexpression and alteration of the PLP/DM20 splicing balance in fibroblasts from Pelizaeus-Merzbacher disease patients. , 2009, Biochimica et biophysica acta.

[35]  L. Notterpek,et al.  Peripheral myelin protein 22 is regulated post‐transcriptionally by miRNA‐29a , 2009, Glia.

[36]  Yue Feng,et al.  Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein , 2010, Proceedings of the National Academy of Sciences.

[37]  J. Lupski,et al.  Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritability. , 2010, American journal of human genetics.

[38]  Rolf Jaggi,et al.  MIQE précis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments , 2010, BMC Molecular Biology.

[39]  D. Radice,et al.  Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial , 2011, The Lancet Neurology.

[40]  B. Ceulemans,et al.  Genetic spectrum of hereditary neuropathies with onset in the first year of life , 2011, Brain : a journal of neurology.

[41]  R. Nagarajan,et al.  Regulation of the PMP22 Gene through an Intronic Enhancer , 2011, The Journal of Neuroscience.

[42]  N. Wood,et al.  Novel peripheral myelin protein 22 (PMP22) micromutations associated with variable phenotypes in Greek patients with Charcot-Marie-Tooth disease. , 2012, Brain : a journal of neurology.

[43]  P. Seeman,et al.  Clinical, In Silico, and Experimental Evidence for Pathogenicity of Two Novel Splice Site Mutations in the SH3TC2 Gene , 2012, Journal of neurogenetics.

[44]  Sooyeon Lee,et al.  The palmitoylation state of PMP22 modulates epithelial cell morphology and migration , 2012, ASN neuro.

[45]  H. Zhu,et al.  The QKI‐PLP pathway controls SIRT2 abundance in CNS myelin , 2012, Glia.

[46]  S. Y. Kim,et al.  A novel double mutation in cis in MFN2 causes Charcot–Marie–Tooth neuropathy type 2A , 2012, neurogenetics.

[47]  G. Pelletier,et al.  Perturbation of myelin basic protein (Mbp) splice variant expression in developing rat cerebellum following perinatal exposure to methylmercury. , 2012, Toxicology letters.

[48]  Ferran Reverter,et al.  Transcriptomics: mRNA and alternative splicing , 2012, Journal of Neuroimmunology.

[49]  B. Taneri,et al.  Biomedical Impact of Splicing Mutations Revealed through Exome Sequencing , 2012, Molecular medicine.

[50]  B. Schlotter-Weigel,et al.  A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. , 2012, Brain : a journal of neurology.

[51]  R. Lewis,et al.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. , 2013, JAMA neurology.

[52]  D. Cooper,et al.  Restoration of the Normal Splicing Pattern of the PLP1 Gene by Means of an Antisense Oligonucleotide Directed against an Exonic Mutation , 2013, PloS one.

[53]  A. Steck,et al.  An essential role of MAG in mediating axon–myelin attachment in Charcot–Marie–Tooth 1A disease , 2013, Neurobiology of Disease.

[54]  M. Zeviani,et al.  SURF1 deficiency causes demyelinating Charcot-Marie-Tooth disease , 2013, Neurology.

[55]  L. Feuk,et al.  RNA-binding protein QKI regulates Glial fibrillary acidic protein expression in human astrocytes. , 2013, Human molecular genetics.

[56]  S. Ryder,et al.  hnRNP A1 and secondary structure coordinate alternative splicing of Mag , 2013, RNA.

[57]  L. Richard,et al.  Peripheral Myelin Protein 22 gene duplication with atypical presentations: A new example of the wide spectrum of Charcot-Marie-Tooth 1A disease , 2014, Neuromuscular Disorders.

[58]  J. Lupski,et al.  The allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals with neuropathy , 2014, Molecular genetics & genomic medicine.

[59]  G. Bergamin,et al.  Mutation Analysis of MFN2, GJB1, MPZ and PMP22 in Italian Patients with Axonal Charcot–Marie–Tooth Disease , 2014, NeuroMolecular Medicine.

[60]  Yue Feng,et al.  A cytoplasmic quaking I isoform regulates the hnRNP F/H-dependent alternative splicing pathway in myelinating glia , 2014, Nucleic acids research.

[61]  D. Radice,et al.  PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. , 2014, Brain : a journal of neurology.

[62]  F. Baas,et al.  Haplotype-specific modulation of a SOX10/CREB response element at the Charcot-Marie-Tooth disease type 4C locus SH3TC2. , 2014, Human molecular genetics.

[63]  J. Lupski,et al.  Mechanism, prevalence, and more severe neuropathy phenotype of the Charcot-Marie-Tooth type 1A triplication. , 2014, American journal of human genetics.

[64]  D. Yanagisawa,et al.  A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease. , 2014, American journal of human genetics.

[65]  S. Gallati.  The Application of Clinical Genetics Dovepress Disease-modifying Genes and Monogenic Disorders: Experience in Cystic Fibrosis , 2022 .

[66]  P. ’. ‘t Hoen,et al.  Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. , 2015, Trends in genetics : TIG.

[67]  Andreas W. Schreiber,et al.  The RNA Binding Protein Quaking Regulates Formation of circRNAs , 2015, Cell.

[68]  P. Hoen,et al.  Alternative mRNA transcription, processing, and translation: insights from RNA sequencing , 2015 .

[69]  P. Cortelli,et al.  Messenger RNA processing is altered in autosomal dominant leukodystrophy , 2015, Human molecular genetics.